Clinical and Ultrasonographic Evaluation of Infantile Periocular Hemangioma Treated With Oral Propranolol. 2019

Mansooreh Jamshidian-Tehrani, and Amin Nabavi, and Mostafa Taghavi, and Shervin Sharif-Kashani, and Abolfazl Kasaee, and Ali Sadeghi-Tari, and Mohammad Mirhosseini, and M Hossein Nowroozzadeh
Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.

OBJECTIVE To evaluate the clinical and ultrasonographic response of periocular infantile capillary hemangioma during treatment with oral propranolol. METHODS Patients with infantile periocular hemangioma and visual or cosmetic concerns were enrolled in this prospective interventional case series. Propranolol was given at a dose of 2 mg/kg per day for at least 6 months. Evaluation of treatment response was performed at month 3 (time point 1) and month 6 (time point 2). Gray scale ultrasonography and color Doppler imaging were performed at baseline and month 3. RESULTS Thirty-one patients with mean age of 4.1 ± 2.3 months were eligible for analysis. Complete or near complete clinical resolution was observed in 4 patients (12.9%) at time point 1 and 21 patients (67.7%) at time point 2. Longitudinal diameter, transverse diameter, thickness, arterial peak systolic velocity, and end diastolic velocity reduced significantly from baseline to 3-month follow up. Complete clinical response at time point 2 was significantly higher in patients with peak systolic velocity reduction >50% from baseline to month 3 than patients with peak systolic velocity reduction of 10% to 50% and <10%. CONCLUSIONS Propranolol is safe and effective for infantile periocular hemangioma. Ultrasonography and color Doppler imaging are useful modalities to monitor and predict the treatment response.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D011433 Propranolol A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs. Dexpropranolol,AY-20694,Anaprilin,Anapriline,Avlocardyl,Betadren,Dociton,Inderal,Obsidan,Obzidan,Propanolol,Propranolol Hydrochloride,Rexigen,AY 20694,AY20694,Hydrochloride, Propranolol
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D005142 Eyelid Neoplasms Tumors of cancer of the EYELIDS. Eyelid Neoplasm,Neoplasm, Eyelid,Neoplasms, Eyelid
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000319 Adrenergic beta-Antagonists Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. Adrenergic beta-Antagonist,Adrenergic beta-Receptor Blockader,Adrenergic beta-Receptor Blockaders,beta-Adrenergic Antagonist,beta-Adrenergic Blocker,beta-Adrenergic Blocking Agent,beta-Adrenergic Blocking Agents,beta-Adrenergic Receptor Blockader,beta-Adrenergic Receptor Blockaders,beta-Adrenoceptor Antagonist,beta-Blockers, Adrenergic,beta-Adrenergic Antagonists,beta-Adrenergic Blockers,beta-Adrenoceptor Antagonists,Adrenergic beta Antagonist,Adrenergic beta Antagonists,Adrenergic beta Receptor Blockader,Adrenergic beta Receptor Blockaders,Adrenergic beta-Blockers,Agent, beta-Adrenergic Blocking,Agents, beta-Adrenergic Blocking,Antagonist, beta-Adrenergic,Antagonist, beta-Adrenoceptor,Antagonists, beta-Adrenergic,Antagonists, beta-Adrenoceptor,Blockader, Adrenergic beta-Receptor,Blockader, beta-Adrenergic Receptor,Blockaders, Adrenergic beta-Receptor,Blockaders, beta-Adrenergic Receptor,Blocker, beta-Adrenergic,Blockers, beta-Adrenergic,Blocking Agent, beta-Adrenergic,Blocking Agents, beta-Adrenergic,Receptor Blockader, beta-Adrenergic,Receptor Blockaders, beta-Adrenergic,beta Adrenergic Antagonist,beta Adrenergic Antagonists,beta Adrenergic Blocker,beta Adrenergic Blockers,beta Adrenergic Blocking Agent,beta Adrenergic Blocking Agents,beta Adrenergic Receptor Blockader,beta Adrenergic Receptor Blockaders,beta Adrenoceptor Antagonist,beta Adrenoceptor Antagonists,beta Blockers, Adrenergic,beta-Antagonist, Adrenergic,beta-Antagonists, Adrenergic,beta-Receptor Blockader, Adrenergic,beta-Receptor Blockaders, Adrenergic
D012878 Skin Neoplasms Tumors or cancer of the SKIN. Cancer of Skin,Skin Cancer,Cancer of the Skin,Neoplasms, Skin,Cancer, Skin,Cancers, Skin,Neoplasm, Skin,Skin Cancers,Skin Neoplasm

Related Publications

Mansooreh Jamshidian-Tehrani, and Amin Nabavi, and Mostafa Taghavi, and Shervin Sharif-Kashani, and Abolfazl Kasaee, and Ali Sadeghi-Tari, and Mohammad Mirhosseini, and M Hossein Nowroozzadeh
January 2018, American journal of ophthalmology,
Mansooreh Jamshidian-Tehrani, and Amin Nabavi, and Mostafa Taghavi, and Shervin Sharif-Kashani, and Abolfazl Kasaee, and Ali Sadeghi-Tari, and Mohammad Mirhosseini, and M Hossein Nowroozzadeh
January 2021, Clinical, cosmetic and investigational dermatology,
Mansooreh Jamshidian-Tehrani, and Amin Nabavi, and Mostafa Taghavi, and Shervin Sharif-Kashani, and Abolfazl Kasaee, and Ali Sadeghi-Tari, and Mohammad Mirhosseini, and M Hossein Nowroozzadeh
February 2011, Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye,
Mansooreh Jamshidian-Tehrani, and Amin Nabavi, and Mostafa Taghavi, and Shervin Sharif-Kashani, and Abolfazl Kasaee, and Ali Sadeghi-Tari, and Mohammad Mirhosseini, and M Hossein Nowroozzadeh
July 2015, The New England journal of medicine,
Mansooreh Jamshidian-Tehrani, and Amin Nabavi, and Mostafa Taghavi, and Shervin Sharif-Kashani, and Abolfazl Kasaee, and Ali Sadeghi-Tari, and Mohammad Mirhosseini, and M Hossein Nowroozzadeh
July 2015, The New England journal of medicine,
Mansooreh Jamshidian-Tehrani, and Amin Nabavi, and Mostafa Taghavi, and Shervin Sharif-Kashani, and Abolfazl Kasaee, and Ali Sadeghi-Tari, and Mohammad Mirhosseini, and M Hossein Nowroozzadeh
April 2024, Asian journal of surgery,
Mansooreh Jamshidian-Tehrani, and Amin Nabavi, and Mostafa Taghavi, and Shervin Sharif-Kashani, and Abolfazl Kasaee, and Ali Sadeghi-Tari, and Mohammad Mirhosseini, and M Hossein Nowroozzadeh
June 2010, Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus,
Mansooreh Jamshidian-Tehrani, and Amin Nabavi, and Mostafa Taghavi, and Shervin Sharif-Kashani, and Abolfazl Kasaee, and Ali Sadeghi-Tari, and Mohammad Mirhosseini, and M Hossein Nowroozzadeh
January 2010, International ophthalmology clinics,
Mansooreh Jamshidian-Tehrani, and Amin Nabavi, and Mostafa Taghavi, and Shervin Sharif-Kashani, and Abolfazl Kasaee, and Ali Sadeghi-Tari, and Mohammad Mirhosseini, and M Hossein Nowroozzadeh
January 2017, Journal of ophthalmic & vision research,
Mansooreh Jamshidian-Tehrani, and Amin Nabavi, and Mostafa Taghavi, and Shervin Sharif-Kashani, and Abolfazl Kasaee, and Ali Sadeghi-Tari, and Mohammad Mirhosseini, and M Hossein Nowroozzadeh
January 2021, Middle East African journal of ophthalmology,
Copied contents to your clipboard!